Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
InMed Pharmaceuticals Inc. (INM)
|
|
| Cash Flow Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Net income | -0.3 | -2.0 | -3.5 | -7.9 | -3.5 | -4.3 | -3.0 | -3.3 |
| Depreciation and amortization | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Asset impairment charges | -0.3 | | 0.6 | | | | | |
| Stock-based compensation | 0.0 | | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 |
| Change in working capital [+] | 2.2 | | 0.1 | 2.4 | -0.9 | 0.3 | -0.5 | 4.8 |
| Accounts receivable | -0.1 | | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Inventories | 0.0 | | 0.1 | -1.1 | -0.4 | -0.5 | | |
| Deferred revenues | | | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Other | 2.3 | | -0.2 | 3.5 | -0.5 | 0.8 | -0.5 | 4.7 |
| Other operating activities | -2.3 | -0.1 | 0.4 | 1.2 | -1.2 | 0.2 | 0.7 | -3.7 |
| Cash from operations | -0.7 | -2.0 | -2.3 | -4.0 | -5.3 | -3.5 | -2.7 | -2.0 |
| |
| Capital expenditures | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | 0.0 |
| Purchases of property and equipment | -0.2 | | | | 0.0 | 0.0 | -0.3 | 0.0 |
| Other cash from investing | 0.1 | | | -0.7 | | 0.3 | | |
| Cash from investing | 0.0 | 0.0 | 0.0 | -0.7 | 0.0 | 0.3 | -0.3 | 0.0 |
| |
| Issuance of common stock, net | | | 6.0 | 5.1 | | 0.0 | 12.0 | |
| Financing costs | | | -0.6 | -0.5 | | -0.2 | -1.1 | -0.1 |
| Other cash from financing | | | -1.1 | -0.6 | 0.0 | -1.0 | -2.2 | -0.2 |
| Cash from financing | 0.0 | 0.0 | 5.4 | 5.1 | 0.0 | -0.8 | 10.9 | -0.1 |
| |
| Free cash flow | -0.8 | -2.0 | -2.3 | -4.0 | -5.4 | -3.6 | -2.9 | -2.0 |
| Per share (diluted) | ($0.33) | ($0.60) | ($2.61) | ($7.22) | ($9.46) | ($0.26) | ($6.03) | ($7.47) |
|